Levomycin | CAS#1403-88-9 | bioactive chemical

MedKoo Cat#: 559193 | Name: Levomycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Levomycin is a bioactive chemical.

Chemical Structure

Levomycin

CAS#1403-88-9

Theoretical Analysis

MedKoo Cat#: 559193

Name: Levomycin

CAS#: 1403-88-9

Chemical Formula: C51H64N12O12S2

Exact Mass: 1100.4208

Molecular Weight: 1101.27

Elemental Analysis: C, 55.62; H, 5.86; N, 15.26; O, 17.43; S, 5.82

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Levomycin;

IUPAC/Chemical Name

N,N'-(11,24-diisopropyl-2,4,12,15,17,25-hexamethyl-27-(methylthio)-3,6,10,13,16,19,23,26-octaoxo-9,22-dioxa-28-thia-2,5,12,15,18,25-hexaazabicyclo[12.12.3]nonacosane-7,20-diyl)bis(quinoxaline-2-carboxamide)

InChi Key

AUJXLBOHYWTPFV-UHFFFAOYSA-N

InChi Code

InChI=1S/C51H64N12O12S2/c1-25(2)38-49(72)74-22-36(59-42(65)34-21-53-30-17-13-15-19-32(30)57-34)44(67)55-28(6)46(69)63(10)40-48(71)62(9)39(26(3)4)50(73)75-23-35(58-41(64)33-20-52-29-16-12-14-18-31(29)56-33)43(66)54-27(5)45(68)60(7)37(47(70)61(38)8)24-77-51(40)76-11/h12-21,25-28,35-40,51H,22-24H2,1-11H3,(H,54,66)(H,55,67)(H,58,64)(H,59,65)

SMILES Code

CC1C(N(C)C2CSC(SC)C(N(C)C(C(C)NC(C(NC(c(cn3)nc4c3cccc4)=O)COC(C(C(C)C)N(C)C2=O)=O)=O)=O)C(N(C)C(C(C)C)C(OCC(NC(c(cn5)nc6c5cccc6)=O)C(N1)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Levomycin is a bioactive chemical.

In vitro activity:

Targeting the HIF-1α/PD-L1 axis in tumor cells reactivated tumor-infiltrating lymphocytes and caused tumor rejection. The HIF-1α inhibitor echinomycin potentiated the cancer immunotherapeutic effects of anti-CTLA-4 therapy, with efficacy comparable to that of anti-CTLA-4 plus anti-PD-1 antibodies. Reference: J Clin Invest. 2022 May 2;132(9):e150846. https://pubmed.ncbi.nlm.nih.gov/35239514/

In vivo activity:

Echinomycin treatment can effectively suppress oncogenic RAS-driven leukemia cell proliferation, using both human leukemia cell lines and a mouse xenograft model. These data suggest that inhibiting the hypoxia pathway could be an effective treatment approach and that echinomycin is a promising targeted drug to attenuate oncogenic RAS-induced cancer phenotypes. Reference: Dis Model Mech. 2022 Feb 1;15(2):dmm048953. https://pubmed.ncbi.nlm.nih.gov/34580712/

Preparing Stock Solutions

The following data is based on the product molecular weight 1,101.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Nishigaki A, Tsubokura H, Ishida M, Hashimoto Y, Yoshida A, Hisamatsu Y, Tsuzuki-Nakao T, Murata H, Okada H. NDRG1 is expressed in human granulosa cells: An implicative role of NDRG1 in the ovary. Reprod Med Biol. 2022 Jan 5;21(1):e12437. doi: 10.1002/rmb2.12437. PMID: 35386369; PMCID: PMC8967294. 2. Bailey CM, Liu Y, Liu M, Du X, Devenport M, Zheng P, Liu Y, Wang Y. Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. J Clin Invest. 2022 May 2;132(9):e150846. doi: 10.1172/JCI150846. PMID: 35239514; PMCID: PMC9057613. 3. Zhu JY, Huang X, Fu Y, Wang Y, Zheng P, Liu Y, Han Z. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes. Dis Model Mech. 2022 Feb 1;15(2):dmm048953. doi: 10.1242/dmm.048953. Epub 2021 Nov 19. PMID: 34580712; PMCID: PMC8617310. 4. Peng G, Wang Y, Ge P, Bailey C, Zhang P, Zhang D, Meng Z, Qi C, Chen Q, Chen J, Niu J, Zheng P, Liu Y, Liu Y. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin. J Exp Clin Cancer Res. 2021 Sep 1;40(1):278. doi: 10.1186/s13046-021-02082-7. PMID: 34470658; PMCID: PMC8411541.

In vitro protocol:

In vivo protocol:

1. Zhu JY, Huang X, Fu Y, Wang Y, Zheng P, Liu Y, Han Z. Pharmacological or genetic inhibition of hypoxia signaling attenuates oncogenic RAS-induced cancer phenotypes. Dis Model Mech. 2022 Feb 1;15(2):dmm048953. doi: 10.1242/dmm.048953. Epub 2021 Nov 19. PMID: 34580712; PMCID: PMC8617310. 2. Peng G, Wang Y, Ge P, Bailey C, Zhang P, Zhang D, Meng Z, Qi C, Chen Q, Chen J, Niu J, Zheng P, Liu Y, Liu Y. The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin. J Exp Clin Cancer Res. 2021 Sep 1;40(1):278. doi: 10.1186/s13046-021-02082-7. PMID: 34470658; PMCID: PMC8411541.

1: Katayama K, Okamura T, Sunadome T, Nakagawa K, Takeda H, Shiro M, Matsuda A, Ichikawa S. Synthesis and biological evaluation of quinaldopeptin. J Org Chem. 2014 Mar 21;79(6):2580-90. doi: 10.1021/jo500039d. Epub 2014 Mar 13. PubMed PMID: 24555872. 2: Lim CL, Nogawa T, Uramoto M, Okano A, Hongo Y, Nakamura T, Koshino H, Takahashi S, Ibrahim D, Osada H. RK-1355A and B, novel quinomycin derivatives isolated from a microbial metabolites fraction library based on NPPlot screening. J Antibiot (Tokyo). 2014 Apr;67(4):323-9. doi: 10.1038/ja.2013.144. Epub 2014 Feb 5. PubMed PMID: 24496142. 3: Zhen X, Gong T, Liu F, Zhang PC, Zhou WQ, Li Y, Zhu P. A New Analogue of Echinomycin and a New Cyclic Dipeptide from a Marine-Derived Streptomyces sp. LS298. Mar Drugs. 2015 Nov 18;13(11):6947-61. doi: 10.3390/md13116947. PubMed PMID: 26593927; PubMed Central PMCID: PMC4663560. 4: Hayase H, Watanabe N, Lim CL, Nogawa T, Komatsuya K, Kita K, Osada H. Inhibition of malaria parasite growth by quinomycin A and its derivatives through DNA-intercalating activity. Biosci Biotechnol Biochem. 2015;79(4):633-5. doi: 10.1080/09168451.2014.987205. Epub 2014 Dec 4. PubMed PMID: 25471083. 5: Singh V, Nand A, Chen C, Li Z, Li SJ, Wang S, Yang M, Merino A, Zhang L, Zhu J. Echinomycin, a potential binder of FKBP12, shows minor effect on calcineurin activity. J Biomol Screen. 2014 Oct;19(9):1275-81. doi: 10.1177/1087057114544742. Epub 2014 Aug 1. PubMed PMID: 25085862. 6: Hotta K, Keegan RM, Ranganathan S, Fang M, Bibby J, Winn MD, Sato M, Lian M, Watanabe K, Rigden DJ, Kim CY. Conversion of a disulfide bond into a thioacetal group during echinomycin biosynthesis. Angew Chem Int Ed Engl. 2014 Jan 13;53(3):824-8. PubMed PMID: 24302672. 7: Sato M, Nakazawa T, Tsunematsu Y, Hotta K, Watanabe K. Echinomycin biosynthesis. Curr Opin Chem Biol. 2013 Aug;17(4):537-45. doi: 10.1016/j.cbpa.2013.06.022. Epub 2013 Jul 12. Review. PubMed PMID: 23856054. 8: Kambayashi S, Igase M, Kobayashi K, Kimura A, Shimokawa Miyama T, Baba K, Noguchi S, Mizuno T, Okuda M. Hypoxia inducible factor 1α expression and effects of its inhibitors in canine lymphoma. J Vet Med Sci. 2015 Nov;77(11):1405-12. doi: 10.1292/jvms.15-0258. Epub 2015 Jun 6. PubMed PMID: 26050843; PubMed Central PMCID: PMC4667657. 9: Ponnurangam S, Dandawate PR, Dhar A, Tawfik OW, Parab RR, Mishra PD, Ranadive P, Sharma R, Mahajan G, Umar S, Weir SJ, Sugumar A, Jensen RA, Padhye SB, Balakrishnan A, Anant S, Subramaniam D. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells. Oncotarget. 2016 Jan 19;7(3):3217-32. doi: 10.18632/oncotarget.6560. PubMed PMID: 26673007; PubMed Central PMCID: PMC4823101. 10: Trimmel K, Cvikl B, Müller HD, Nürnberger S, Gruber R, Moritz A, Agis H. L-mimosine increases the production of vascular endothelial growth factor in human tooth slice organ culture model. Int Endod J. 2015 Mar;48(3):252-60. doi: 10.1111/iej.12307. Epub 2014 Jun 28. PubMed PMID: 24786562. 11: Ichikawa S, Okamura T, Matsuda A. Total synthesis of quinaldopeptin and its analogues. J Org Chem. 2013 Dec 20;78(24):12662-70. doi: 10.1021/jo402267r. Epub 2013 Nov 27. PubMed PMID: 24236405. 12: Rackham BD, Howell LA, Round AN, Searcey M. Non-covalent duplex to duplex crosslinking of DNA in solution revealed by single molecule force spectroscopy. Org Biomol Chem. 2013 Dec 28;11(48):8340-7. doi: 10.1039/c3ob42009d. Epub 2013 Oct 25. PubMed PMID: 24158749. 13: KATAGIRI K, SHOJI J, YOSHISA T. Identity of levomycin and quinomycin A (echimomycin). J Antibiot (Tokyo). 1962 Nov;15:273. PubMed PMID: 14042112. 14: ISHIHARA S, UTAHARA R, SUZUKI M, OKAMI Y, UMEZAWA H. Studies on actinoleukin; relation to echinomycin and levomycin. J Antibiot (Tokyo). 1958 Jul;11(4):160-1. PubMed PMID: 13587404. 15: Wan YY, Zhang JF, Yang ZJ, Jiang LP, Wei YF, Lai QN, Wang JB, Xin HB, Han XJ. Involvement of Drp1 in hypoxia-induced migration of human glioblastoma U251 cells. Oncol Rep. 2014 Aug;32(2):619-26. doi: 10.3892/or.2014.3235. Epub 2014 Jun 5. PubMed PMID: 24899388. 16: MOROZ AF, SHIBAEVA IV. [EFFECT OF LEVOMYCIN AND CHLORTETRACYCLINE ON THE TRANSAMINASE ACTIVITY OF STAPHYLOCOCCI SENSITIVE AND RESISTANT TO THESE ANTIBIOTICS]. Antibiotiki. 1964 Jul;9:616-21. Russian. PubMed PMID: 14232880. 17: Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, Caligiuri MA, Zheng P, Liu Y. Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells. Blood. 2014 Aug 14;124(7):1127-35. doi: 10.1182/blood-2013-12-544221. Epub 2014 Jul 3. PubMed PMID: 24994068; PubMed Central PMCID: PMC4133485. 18: SHEMIAKIN MM, KOLOSOV MN, LEVITOV MM, GERMANOVA KI, KARAPETIAN MG, SHVETSOV IuB, BAMDAS EM. [Correlation between structure, antibacterial action, and mechanism of action of chloromycetin (levomycin)]. Dokl Akad Nauk SSSR. 1955 Jun 11;102(5):953-6. Russian. PubMed PMID: 13251124. 19: Tsuzuki T, Okada H, Shindoh H, Shimoi K, Nishigaki A, Kanzaki H. Effects of the hypoxia-inducible factor-1 inhibitor echinomycin on vascular endothelial growth factor production and apoptosis in human ectopic endometriotic stromal cells. Gynecol Endocrinol. 2016;32(4):323-8. doi: 10.3109/09513590.2015.1121225. Epub 2015 Dec 10. PubMed PMID: 26654708. 20: MEBEL BD. [Treatment of typhoid-paratyphoid diseases with ACTH in combination with levomycin]. Sov Med. 1959 Feb;23(2):70-7. Russian. PubMed PMID: 13646981.